During a trip to the Orphan Drug Conference in Washington D.C., I met with Anton Simeonov, Ph.D., scientific director at the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH). NCATS tackles rare diseases through collaborative research to study the commonalities and underlying molecular causes of these disorders. This approach has the potential to speed the development of treatments for multiple diseases simultaneously and ultimately help more patients more quickly.
Anton Simeonov PhD - NCATS Scientific Director.
Simeonov discussed NCATS’ Division of Pre-Clinical Innovation (DPI), which features laboratories staffed with teams of biologists, medicinal and analytical chemists, automation specialists, and informatics specialists. I learned that one of the first steps in drug development and toxicity testing is creating test systems (assays) on which to evaluate the effects of chemical compounds on cellular, molecular or biochemical processes of interest.
Fluid robotics for the 356 well plate. The basins are for washes to allow for transfer of drug/chemicals from different assays.
NCATS researchers screen assays against hundreds of thousands of compounds a week using high-throughput screening robots (pictured). Typically, it might take weeks or months to test the same number of compounds in an academic setting. The ultimate goal is to develop probes, which help researchers further explore protein and cell functions and biological processes. These probes can become potential therapeutic candidates in the drug development pipeline.
NCATS continues to seek collaborations for its work. Through such collaborations, the Center aims to improve translational science by developing new approaches, technologies, resources and models; demonstrating their usefulness; and disseminating the resulting data, analyses and methodologies to the broad scientific community. For more information, connect with NCATS and visit https://ncats.nih.gov.